Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study.
Vincent JoergBernhard ScheinerAntonio D'AlessioClaudia Angela Maria FulgenziMartin SchönleinLorenz KocheiseAnsgar Wilhelm LohseSamuel HuberHenning WegeAhmed KasebYinghong WangAntony MathewAndrew KuangMahvish MuzaffarYehia I AbugabalShadi ChamseddineSamuel PhenJaekyung CheonPei-Chang LeeLorenz BalcarAnja KrallCelina AngLinda WuAnwaar SaeedYi-Hsiang HuangBertram BengschLorenza RimassaArndt WeinmannRudolf StauberJames KorolewiczMatthias PinterAmit G SingalHong Jae ChonDavid J PinatoKornelius SchulzeJohann von FeldenPublished in: Hepatology communications (2023)
In this observational study, AB emerges as a safe and efficacious treatment option in patients with HCC previously treated with other systemic therapy.